These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18397345)

  • 1. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
    Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
    Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib inhibits human osteoclastogenesis.
    von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
    Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
    Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Combaret V; Boyault S; Iacono I; Brejon S; Rousseau R; Puisieux A
    Mol Cancer; 2008 Jun; 7():50. PubMed ID: 18534018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
    Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
    Hideshima T; Richardson P; Chauhan D; Palombella VJ; Elliott PJ; Adams J; Anderson KC
    Cancer Res; 2001 Apr; 61(7):3071-6. PubMed ID: 11306489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
    Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
    Hongming H; Jian H
    Leuk Res; 2009 Jan; 33(1):115-22. PubMed ID: 18778854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
    Udi J; Schüler J; Wider D; Ihorst G; Catusse J; Waldschmidt J; Schnerch D; Follo M; Wäsch R; Engelhardt M
    Br J Haematol; 2013 Apr; 161(1):104-16. PubMed ID: 23384035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
    Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
    ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.